UK-based pharmaceutical firm AstraZeneca denied recent reports that the company was in talks to possible be acquired by US rival Pfizer, a deal experts valued at $101 billion – one of the largest-ever for the industry.
According to one source, Pfizer had made numerous informal merger advances to the UK firm. Reports placed one of those offers at about $101 billion, a deal that would surpass Pfizer’s largest buyout to date, its $90 billion acquisition of Warner-Lambert.
While earlier reports noted that AstraZeneca had dismissed the buyout offers, some experts predict a potential deal could emerge in the future. But additional sources say the companies are not in merger talks as of now.
Meanwhile, reports say Pfizer has agreed to settle a class action pay-for-delay lawsuit with a $190 million offer.
According to court documents filed Monday, the company was accused of paying the generic maker of its epilepsy drug Neurontin to keep the cheaper competitor off pharmaceutical shelves, an agreement known as pay-for-delay.
The lawsuit was filed in 2002.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Business Secretary Calls for More Agile Competition Regulator
Feb 13, 2025 by
CPI
Germany’s Antitrust Regulator Raises Concerns Over Apple’s App Tracking Policies
Feb 13, 2025 by
CPI
$60 Billion Nissan-Honda Merger Falls Apart
Feb 13, 2025 by
CPI
DOJ Moves to End Protections for Three Regulatory Agencies
Feb 13, 2025 by
CPI
Meta to Allow Rivals to List Ads on Facebook Marketplace Following EU Fine
Feb 13, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon